Form 8-K - Current report:
SEC Accession No. 0001628280-24-046223
Filing Date
2024-11-07
Accepted
2024-11-07 16:01:28
Documents
13
Period of Report
2024-11-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K aqst-20241101.htm   iXBRL 8-K 25588
  Complete submission text file 0001628280-24-046223.txt   147714

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aqst-20241101.xsd EX-101.SCH 1776
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aqst-20241101_lab.xml EX-101.LAB 21629
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aqst-20241101_pre.xml EX-101.PRE 12504
15 EXTRACTED XBRL INSTANCE DOCUMENT aqst-20241101_htm.xml XML 2719
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Filer) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38599 | Film No.: 241435384
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)